{"id":"NCT03426267","sponsor":"Sun Pharma Advanced Research Company Limited","briefTitle":"Evaluation of Efficacy and Safety of SDN-037","officialTitle":"A Randomized, Double-Masked, Parallel Group, Multicenter, Study To Evaluate Efficacy And Safety of SDN -037 Twice Daily Compared With Vehicle For The Treatment Of Inflammation And Pain Associated With Ocular Surgery.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-28","primaryCompletion":"2020-03-05","completion":"2020-03-05","firstPosted":"2018-02-08","resultsPosted":"2021-05-17","lastUpdate":"2021-05-17"},"enrollment":325,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Inflammation and Pain Associated With Ocular Surgery"],"interventions":[{"type":"DRUG","name":"SDN-037","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SDN-037","type":"EXPERIMENTAL"},{"label":"vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The efficacy and safety of SDN-037 twice daily will be evaluated and compared with vehicle for the treatment of inflammation and pain associated with ocular surgery.","primaryOutcome":{"measure":"Subjects With an Anterior Chamber Cell Grade of 0 at Day 15","timeFrame":"Day 15","effectByArm":[{"arm":"SDN-037","deltaMin":96,"sd":null},{"arm":"Vehicle","deltaMin":30,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":19,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":154},"commonTop":["Anterior chamber cell","Anterior chamber flare","Visual acuity reduced","Conjunctival hyperaemia","Corneal oedema"]}}